Not Signed In -
Assistive Devices |
Wheelchairs |
Clinical Trial: Trial of a Novel Fibrinolytic (alfimeprase) to Clear Thrombosed Vascular Access Devices
This study is currently recruiting patients.
|
Purpose
This trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). The trial compares a new blood clot dissolving agent (alfimeprase) against the currently used treatment.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Catheters, Indwelling | Drug: Alfimeprase | Phase II |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Subjects must:
- have a dysfunctional Central Venous Access Device (CVAD) defined as unable to withdraw 3 mL blood
- have had the device in place for > 48 hours
- be clinically stable
- be 18 or older
- give informed consent
Location and Contact Information
Luis Pena 408-215-1000 lpena@nuvelo.com
Ohio
Cleveland Clinic Foundation, Cleveland, Ohio, United States; Recruiting
Brenda Clingman 216-444-7698 clingmb@cc.ccf.org
More Information
Alfimeprase Information
Record last reviewed: November 2003
Last Updated: October 25, 2004
Record first received: November 21, 2003
ClinicalTrials.gov Identifier: NCT00073515
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- ABLEDATA: Get Product Info (National Institute on Disability and Rehabilitation Research)
- Access Board
email this page
print this page
bookmark this page
feedback on this page
